Compounded semaglutide with B12 is not lawful because of the B12. Under section 503A, what takes a compounded version of a commercially available drug out of the “essentially a copy” bar is a prescriber’s determination that a change makes a significant difference for one identified patient. On September 18, 2026, FDA told a large 503A pharmacy that its add-on formulations looked “pretextual.” As of October 2026, that letter is the clearest statement of how FDA reads these prescriptions.
What the Empower Pharmacy warning letter says about compounded semaglutide with B12
Warning letter 738238 went to Empower Clinic Services, LLC dba Empower Pharmacy after a November 2025 inspection. It names three products: semaglutide/cyanocobalamin and two strengths of tirzepatide/niacinamide. FDA says they “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products,” compounded “regularly and in inordinate amounts.”
The sentence operators are quoting is this one: “The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual.”
FDA lists three kinds of evidence:
- Prescriptions with no prescriber determination of significant difference at all.
- Determinations “repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber.”
- The volume of particular products compounded and orders filled.
It then names the mechanism: prescriptions generated “through third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference” call the individual nature of the determination into question.
The letter also notes that FDA’s enforcement discretion for 503A copies ended March 5, 2025 for tirzepatide injection and April 24, 2025 for semaglutide injection.
A significant difference statement under 503A belongs to one prescriber and one patient
The statute, as the letter quotes it, says a compounded drug is not essentially a copy if “there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner.”
FDA’s January 2018 guidance says no particular format is required, provided “the prescription makes clear that the prescriber identified the relevant change and the significant difference that the change will produce for the patient.” It adds that a lower price is not a significant difference.
| What FDA’s 2018 guidance accepts | What the September 2026 letter flagged | |
|---|---|---|
| Who writes it | The prescriber, on the prescription | A statement picked from a platform menu |
| What it says | The change and why this patient needs it, such as “No Dye X, patient allergy” | The same sentence across many records |
| What it ties to | A formulation change that matters to the patient | An added ingredient with no patient-specific reason recorded |
| Scale | Individual prescriptions | Monthly order volumes FDA redacted but called inordinate |
The guidance also lists, as a sign of copying, a compounder that “offers pre-printed prescription pads” for a copy “without making a determination” of significant difference. A dropdown is the 2026 version of that pad.
Compounded tirzepatide with niacinamide is treated the same way
Two of the three products in the letter are tirzepatide with niacinamide. Neither add-on was treated as a difference in itself. The letter never asks whether B12 or niacinamide is useful. It asks whether anyone decided it was useful for this patient and wrote that down.
The four-or-fewer prescriptions policy does not rescue a volume program
The copies bar applies to compounding “regularly or in inordinate amounts.” FDA’s guidance says that, as a matter of enforcement policy, it does not intend to act where “the compounder fills four or fewer prescriptions for the relevant compounded drug product in a calendar month.” Prescriptions that carry a real significant-difference determination do not count toward the four.
This is a policy about the pharmacy’s monthly total. It is not a safe harbor for a clinic, and it offers nothing to a program sending hundreds of orders for the same vial.
Advertising the add-on is a separate misbranding problem
Under section 502(bb) of the Act, a compounded drug is misbranded “If the advertising or promotion of a compounded drug is false or misleading in any particular.” FDA has used that section against telehealth sellers.
Its June 8, 2026 letter to Altru Telehealth quoted this website claim as a violation: “Compounded semaglutide combines the FDA approved active ingredient semaglutide with a body safe vitamin such as B12.” FDA’s objection was that the claim represents the compounded product as approved or evaluated when it is not. The same letter objected to calling a compounding pharmacy “FDA approved,” because the Act creates no such designation for pharmacies or outsourcing facilities.
So there are two exposures. The pharmacy carries the 503A exposure for the copy. If you run an online brand, the misbranding exposure for the claim is yours.
The compounders’ argument deserves a fair statement
The statute assigns the determination to “the prescribing practitioner,” and the guidance says that “FDA generally does not intend to question prescriber determinations that are documented in a prescription or notation.” On that reading, if a licensed prescriber selects a reason and signs, the condition is met, and FDA is second-guessing medical judgment it promised to leave alone. A compounder can also argue that volume shows demand and nothing more, and the letter itself hedges with “appear” and “suggests.” A warning letter states the agency’s position and invites a response.
The same guidance paragraph answers the first point: FDA will consider whether the prescription “documents that the determination was made.” A sentence chosen from a list before the patient is known is weak evidence that anyone made one.
Where our position differs from market practice
A setup we see often is a platform default: every weight-management order routes to a combination vial, and the significant-difference field is pre-filled. We do not think that survives this letter.
Our position is that the prescriber writes the reason in their own words for the patient in front of them, and that the reason must connect the formulation change to that patient. Where there is no such reason, the patient gets the approved product or does not get the drug. That costs volume. It is the position we hold as a medical director to the programs we supervise. Our published clinical standards list the kinds of programs we decline to support.
A decision sequence for a compounded GLP-1 order
- Is there an approved product in the same active ingredient, strength range and route? For semaglutide and tirzepatide injection, yes.
- Is the compounded formulation changed from it? Name the change.
- Has the prescriber determined that the change makes a significant difference for this patient? If no, stop.
- Is that determination on the prescription, in the prescriber’s words, naming the change and the reason?
- Would the same sentence appear on your next fifty orders? If yes, treat it as a template and go back to step 3.
- Does your marketing describe the product as compounded, without implying approval or sameness?
What this means for you
Pull twenty recent compounded GLP-1 prescriptions from your weight management program and read the significant-difference field on each. If they match word for word, you have the pattern FDA described. Ask your platform vendor whether that field can be free text only, and turn the menu off. Ask your pharmacy how it documents determinations and what it does with an order that lacks one. Then read your own ad copy for the Altru sentence.
Frequently asked questions
Is compounded semaglutide with B12 legal?
Adding B12 does not by itself make it lawful. As of October 2026, a 503A pharmacy may not regularly compound essentially a copy of approved semaglutide. The exception requires a prescriber’s documented determination that a formulation change produces a significant difference for an identified patient. FDA’s September 18, 2026 Empower letter called high-volume add-on formulations pretextual.
What did the Empower Pharmacy warning letter say?
FDA letter 738238 says semaglutide/cyanocobalamin and tirzepatide/niacinamide products appear to be essentially copies of approved drugs, compounded regularly and in inordinate amounts. It cites missing determinations, determinations repeated verbatim, and platforms offering pre-selected menu options. It also cites sterile processing and quality deficiencies.
What is a significant difference statement under 503A?
It is the prescriber’s record, on the prescription, that a change to the formulation produces a significant difference for a specific patient. FDA’s 2018 guidance requires it to identify the change and the difference. Examples FDA accepts include a dye allergy or an inability to swallow a tablet. Lower price does not qualify.
Is compounded tirzepatide with niacinamide treated differently?
No. Two of the three products named in the Empower letter are tirzepatide with niacinamide, and FDA applied the same analysis as for semaglutide with cyanocobalamin. The added ingredient was not treated as a difference in itself. The question was whether a prescriber made an individual determination.
Can a pharmacy rely on the four-prescriptions-a-month policy?
FDA’s 2018 guidance says it does not intend to act against a compounder that fills four or fewer prescriptions for a relevant copy in a calendar month. That is enforcement policy for the pharmacy’s total, and FDA may change it. It does not support a clinic program ordering the same compounded product at scale.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.